Santarus, Shore Therapeutics sales and marketing update

Shore granted Santarus exclusive rights to commercialize 40 and 120 mg Fenoglide fenofibrate in the U.S. Santarus will pay $11 million up

Read the full 221 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE